Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its joint venture Chongqing Mingdao Haoyue Biotechnology Co., Ltd has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its nasal spray COVID-19 neutralizing antibody MY-586.
Drug Mechanism and Advantages
MY-586 is described as a first-in-class drug that allows for non-invasive local drug use in the form of a nasal spray. The broad-spectrum and potent antibodies in the spray concentrate on the nasal mucosa and other viral invasion sites to form a protective film, neutralizing virus particles and shielding human cells from COVID-19 infection and further spread. Additionally, the neutralizing antibody features a stable process, convenient production, low cost, and strong accessibility, making it a promising candidate for widespread use.
Future Outlook
With the NMPA’s approval, Ausper Biopharma is poised to advance MY-586 into clinical trials, marking a significant step in the development of non-invasive treatments for COVID-19. The company aims to leverage the drug’s unique delivery method and cost-effective production to contribute to global efforts in combating the pandemic.-Fineline Info & Tech
